Zealand Pharma A/S
Zealand Pharma A/S Fundamental Analysis
Zealand Pharma A/S (ZLDPF) shows strong financial fundamentals with a PE ratio of 3.95, profit margin of 70.06%, and ROE of 47.93%. The company generates $9.2B in annual revenue with strong year-over-year growth of 145.99%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 99.7/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze ZLDPF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentZLDPF demonstrates superior asset utilization.
Valuation Score
ExcellentZLDPF trades at attractive valuation levels.
Growth Score
ModerateZLDPF shows steady but slowing expansion.
Financial Health Score
ExcellentZLDPF maintains a strong and stable balance sheet.
Profitability Score
ExcellentZLDPF achieves industry-leading margins.
Key Financial Metrics
Is ZLDPF Expensive or Cheap?
P/E Ratio
ZLDPF trades at 3.95 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ZLDPF's PEG of -0.86 indicates potential undervaluation.
Price to Book
The market values Zealand Pharma A/S at 1.72 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.25 times EBITDA. This is generally considered low.
How Well Does ZLDPF Make Money?
Net Profit Margin
For every $100 in sales, Zealand Pharma A/S keeps $70.06 as profit after all expenses.
Operating Margin
Core operations generate 75.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $47.93 in profit for every $100 of shareholder equity.
ROA
Zealand Pharma A/S generates $39.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Zealand Pharma A/S generates strong operating cash flow of $6.89B, reflecting robust business health.
Free Cash Flow
Zealand Pharma A/S generates strong free cash flow of $6.86B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $97.38 in free cash annually.
FCF Yield
ZLDPF converts 27.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
3.95
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.86
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.72
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
23.57
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.48
vs 25 benchmark
ROA
Return on assets percentage
0.39
vs 25 benchmark
ROCE
Return on capital employed
0.44
vs 25 benchmark
How ZLDPF Stacks Against Its Sector Peers
| Metric | ZLDPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 3.95 | 29.45 | Better (Cheaper) |
| ROE | 47.93% | 779.00% | Weak |
| Net Margin | 70.06% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 23.57 | 4.65 | Strong Liquidity |
| ROA | 39.31% | -19344.00% (disorted) | Strong |
ZLDPF outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Zealand Pharma A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1319.46%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
514.90%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
616.17%
Industry Style: Defensive, Growth, Innovation
High Growth